Kura Oncology, Inc. (NASDAQ:KURA) Insider Mollie Leoni Sells 4,963 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kura Oncology Stock Performance

Shares of KURA stock opened at $7.77 on Wednesday. Kura Oncology, Inc. has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The stock’s 50-day moving average is $9.23 and its two-hundred day moving average is $15.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market cap of $604.20 million, a P/E ratio of -3.29 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same period last year, the company posted ($0.50) earnings per share. Analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. nVerses Capital LLC bought a new stake in Kura Oncology in the third quarter worth $25,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after acquiring an additional 1,750 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology during the 3rd quarter worth about $146,000. Quarry LP acquired a new position in shares of Kura Oncology during the 2nd quarter valued at about $196,000. Finally, Erste Asset Management GmbH bought a new position in shares of Kura Oncology in the 3rd quarter valued at approximately $215,000.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. HC Wainwright lifted their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, November 21st. Bank of America reduced their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.